Adagene Inc
$ 3.35
4.04%
24 Feb - close price
- Market Cap 84,836,000 USD
- Current Price $ 3.35
- High / Low $ 3.49 / 3.12
- Stock P/E N/A
- Book Value 0.80
- EPS -0.64
- Next Earning Report 2026-03-23
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.63 %
- 52 Week High 3.53
- 52 Week Low 1.30
About
Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.
Analyst Target Price
$9.51
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-03 | 2025-08-12 | 2025-05-28 | 2025-03-24 | 2024-11-27 | 2024-07-25 | 2024-05-29 | 2024-03-29 | 2023-11-29 | 2023-08-31 | 2023-05-31 | 2023-03-28 |
| Reported EPS | 0 | -0.23 | -0.17 | -0.29 | 0 | -0.285 | 0 | -0.27 | -0.42 | -1.48 | -0.38 | -1.55 |
| Estimated EPS | -0.18 | -0.33 | -0.17 | -0.47 | 0 | -0.26 | 0 | -0.27 | -0.42 | -0.93 | -0.38 | -0.4 |
| Surprise | 0.18 | 0.1 | 0 | 0.18 | 0 | -0.025 | 0 | 0 | 0 | -0.55 | 0 | -1.15 |
| Surprise Percentage | 100% | 30.303% | 0% | 38.2979% | None% | -9.6154% | None% | 0% | 0% | -59.1398% | 0% | -287.5% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-23 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADAG
2026-02-18 09:53:12
Adagene Inc. announced that its Chief Strategy Officer, Mickael Chane-Du, will participate in investor meetings and fireside chats at two upcoming virtual and in-person conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, and the Leerink Global Healthcare Conference from March 8-11, 2026. The company, a clinical-stage biotechnology firm focused on novel antibody-based cancer immunotherapies, will make webcasts of its presentations available on its investor relations website for 30 days.
2026-02-17 14:28:05
Adagene (Nasdaq: ADAG) announced that its Chief Strategy Officer, Mickael Chane-Du, will participate in investor meetings and fireside chats at two upcoming conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, and the Leerink Global Healthcare Conference on March 9, 2026. Webcasts of these presentations will be available for remote access on the company's website. The company also highlighted its recent presentation at the Guggenheim Emerging Outlook: Biotech Summit 2026.
2026-02-16 12:57:18
Moderna (MRNA) shares rose 5.3% on Friday, February 13, as investors renewed interest in large-cap biotech companies, highlighting confidence in its vaccine platform and long-term growth narrative. The gain, alongside peers Adagene Inc. (ADAG) and Vertex Pharmaceuticals Incorporated (VRTX), suggests a broader recalibration in risk appetite towards innovative healthcare leaders. Institutional buying and short-covering appear to have contributed to the stock's strength, indicating Wall Street's reception to biotech firms with durable platforms.
2026-02-11 12:27:27
Short interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) saw a significant increase of 283.2% in January, reaching 62,815 shares, though this still represents a low percentage of the float and a very short days-to-cover ratio. The company's stock currently trades around $2.98, with analysts holding an average "Buy" rating and a consensus price target of $7.67. Institutional investors have also shown increased interest, with several hedge funds acquiring new stakes or growing existing holdings.
2026-01-31 15:02:42
Short interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) significantly decreased by 31.1% in January, totaling 16,394 shares with a low days-to-cover ratio of 0.3. Analysts maintain a "Buy" consensus rating for ADAG, with a target price of $7.67, though individual ratings range from Strong Buy to Sell. The company's shares are trading near their 52-week range, with hedge funds holding approximately 9.5% of the stock.
2026-01-29 21:56:00
Retail investors collectively own 41% of Adagene Inc. (ADAG), making them the largest shareholder group. This group significantly benefited from the company's 64% stock increase last week, which pushed its market cap to US$117 million. Despite minimal institutional ownership, the top six shareholders control over half the company, with Han 2020 Irrevocable Trust being the largest individual holder at 16%.
